Last 12 months
Inside the activity.
1 purchase rows · 14 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 7 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 1 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 17, 2021 Filed Sep 17, 2021 20:34 UTC |
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
RA Capital Nexus Fund, L.P.Director · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
|
ConversionCommon Stock | 442,721 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-116944 · tm2127913-1_4.xml · nonDerivative · entry 4 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director · 10% owner Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 442,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F4 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, the Nexus Fund, and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F5 · ownership.nature: These securities are held directly by the Account. Read SEC document |
| September 17, 2021 Filed Sep 17, 2021 20:34 UTC |
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
RA Capital Nexus Fund, L.P.Director · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
|
ConversionCommon Stock | 1,496,613 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-116944 · tm2127913-1_4.xml · nonDerivative · entry 3 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director · 10% owner Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 1,496,613 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3 · ownership.nature: These securities are held directly by RA Capital Nexus Fund, L.P. (the "Nexus Fund"). F4 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, the Nexus Fund, and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| September 17, 2021 Filed Sep 17, 2021 20:34 UTC |
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
RA Capital Nexus Fund, L.P.Director · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
|
PurchaseCommon Stock | 1,250,000 | $16.00 | $20,000,000.00 |
DisclosureSEC source: 0001104659-21-116944 · tm2127913-1_4.xml · nonDerivative · entry 2 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director · 10% owner Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 5,297,120 F2 · ownership.nature: These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). F4 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, the Nexus Fund, and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| September 17, 2021 Filed Sep 17, 2021 20:34 UTC |
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
RA Capital Nexus Fund, L.P.Director · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
|
ConversionCommon Stock | 4,047,120 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-116944 · tm2127913-1_4.xml · nonDerivative · entry 1 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director · 10% owner Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 4,047,120 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). F4 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, the Nexus Fund, and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| September 17, 2021 Filed Sep 20, 2021 21:16 UTC |
Canaan XI L.P.10% owner
Canaan Partners XI LLC10% owner
|
ConversionSeries B Preferred Stock · Derivative | 182,258 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-036606 · doc4.xml · derivative · entry 5 Canaan XI L.P. · CIK 0001712417 · 10% owner Canaan Partners XI LLC · CIK 0001850694 · 10% owner Canaan 2020+ Co-Investment L.P. Series 7 · CIK 0001882023 · 10% owner Canaan Partners 2020+ Co-Investment LLC · CIK 0001881618 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 473,396 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3 · ownership.direct: The shares are held directly by Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7"). The sole general partner of Canaan Series 7 is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 17, 2021 Filed Sep 20, 2021 21:16 UTC |
Canaan XI L.P.10% owner
Canaan Partners XI LLC10% owner
|
ConversionSeries B Preferred Stock · Derivative | 182,257 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-036606 · doc4.xml · derivative · entry 4 Canaan XI L.P. · CIK 0001712417 · 10% owner Canaan Partners XI LLC · CIK 0001850694 · 10% owner Canaan 2020+ Co-Investment L.P. Series 7 · CIK 0001882023 · 10% owner Canaan Partners 2020+ Co-Investment LLC · CIK 0001881618 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 473,394 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.direct: The shares are held directly by Canaan XI L.P. ("Canaan XI"). The sole general partner of Canaan XI is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 17, 2021 Filed Sep 20, 2021 21:16 UTC |
Canaan XI L.P.10% owner
Canaan Partners XI LLC10% owner
|
ConversionSeries A Preferred Stock · Derivative | 1,333,334 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-036606 · doc4.xml · derivative · entry 3 Canaan XI L.P. · CIK 0001712417 · 10% owner Canaan Partners XI LLC · CIK 0001850694 · 10% owner Canaan 2020+ Co-Investment L.P. Series 7 · CIK 0001882023 · 10% owner Canaan Partners 2020+ Co-Investment LLC · CIK 0001881618 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,463,201 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.direct: The shares are held directly by Canaan XI L.P. ("Canaan XI"). The sole general partner of Canaan XI is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 17, 2021 Filed Sep 20, 2021 21:16 UTC |
Canaan XI L.P.10% owner
Canaan Partners XI LLC10% owner
|
ConversionCommon Stock | 473,396 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-036606 · doc4.xml · nonDerivative · entry 2 Canaan XI L.P. · CIK 0001712417 · 10% owner Canaan Partners XI LLC · CIK 0001850694 · 10% owner Canaan 2020+ Co-Investment L.P. Series 7 · CIK 0001882023 · 10% owner Canaan Partners 2020+ Co-Investment LLC · CIK 0001881618 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 473,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3 · ownership.direct: The shares are held directly by Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7"). The sole general partner of Canaan Series 7 is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 17, 2021 Filed Sep 20, 2021 21:16 UTC |
Canaan XI L.P.10% owner
Canaan Partners XI LLC10% owner
|
ConversionCommon Stock | 3,936,595 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-036606 · doc4.xml · nonDerivative · entry 1 Canaan XI L.P. · CIK 0001712417 · 10% owner Canaan Partners XI LLC · CIK 0001850694 · 10% owner Canaan 2020+ Co-Investment L.P. Series 7 · CIK 0001882023 · 10% owner Canaan Partners 2020+ Co-Investment LLC · CIK 0001881618 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,936,595 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.direct: The shares are held directly by Canaan XI L.P. ("Canaan XI"). The sole general partner of Canaan XI is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 17, 2021 Filed Sep 20, 2021 22:36 UTC Amendment |
Kjellson Nina SDirector
|
ConversionSeries B Preferred Stock · Derivative | 182,258 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-036637 · doc4a.xml · derivative · entry 5 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By 2020+ Co-Investment L.P. - Series 7 Disclosed balance after: 0 Underlying: Common Stock · 473,396 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3 · ownership.nature: The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 17, 2021 Filed Sep 20, 2021 22:36 UTC Amendment |
Kjellson Nina SDirector
|
ConversionSeries B Preferred Stock · Derivative | 182,257 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-036637 · doc4a.xml · derivative · entry 4 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Canaan XI L.P. Disclosed balance after: 0 Underlying: Common Stock · 473,394 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 17, 2021 Filed Sep 20, 2021 22:36 UTC Amendment |
Kjellson Nina SDirector
|
ConversionSeries A Preferred Stock · Derivative | 1,333,334 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-036637 · doc4a.xml · derivative · entry 3 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Canaan XI L.P. Disclosed balance after: 0 Underlying: Common Stock · 3,463,201 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 17, 2021 Filed Sep 20, 2021 22:36 UTC Amendment |
Kjellson Nina SDirector
|
ConversionCommon Stock | 473,396 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-036637 · doc4a.xml · nonDerivative · entry 2 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By 2020+ Co-Investment L.P. - Series 7 Disclosed balance after: 473,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3 · ownership.nature: The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 17, 2021 Filed Sep 20, 2021 22:36 UTC Amendment |
Kjellson Nina SDirector
|
ConversionCommon Stock | 3,936,595 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-036637 · doc4a.xml · nonDerivative · entry 1 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Canaan XI L.P. Disclosed balance after: 3,936,595 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 17, 2021 Filed Sep 21, 2021 20:03 UTC |
Cormorant Asset Management, LPFormer 10% Owner
Chen BihuaDirector · Former 10% Owner
Cormorant Global Healthcare Master Fund, LPFormer 10% Owner
Cormorant Private Healthcare Fund III LPFormer 10% Owner
|
ConversionSeries B Convertible Preferred Stock · Derivative | 757,432 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-017389 · doc1.xml · derivative · entry 3 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · Director · Former 10% Owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · Former 10% Owner Cormorant Private Healthcare Fund III LP · CIK 0001817320 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 757,432 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series B Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · price: Shares of Series B Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Shares of Series B Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Shares of Series B Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund III, LP ("Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F5 · ownership.nature: The Series B Convertible Preferred Stock represented, on an as-converted basis, (i) 165,877 shares held by the Master Fund, (ii) 578,111 shares held by Fund III, and (iii) 13,444 shares held by the Account. Read SEC document |
| September 17, 2021 Filed Sep 21, 2021 20:03 UTC |
Cormorant Asset Management, LPFormer 10% Owner
Chen BihuaDirector · Former 10% Owner
Cormorant Global Healthcare Master Fund, LPFormer 10% Owner
Cormorant Private Healthcare Fund III LPFormer 10% Owner
|
PurchaseCommon Stock | 312,500 | $16.00 | $5,000,000.00 |
DisclosureSEC source: 0001567619-21-017389 · doc1.xml · nonDerivative · entry 2 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · Director · Former 10% Owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · Former 10% Owner Cormorant Private Healthcare Fund III LP · CIK 0001817320 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,069,932 F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund III, LP ("Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F4 · ownership.nature: Shares reported herein as purchased on September 17, 2021 represent 312,500 shares purchased by the Master Fund. Read SEC document |
| September 17, 2021 Filed Sep 21, 2021 20:03 UTC |
Cormorant Asset Management, LPFormer 10% Owner
Chen BihuaDirector · Former 10% Owner
Cormorant Global Healthcare Master Fund, LPFormer 10% Owner
Cormorant Private Healthcare Fund III LPFormer 10% Owner
|
ConversionCommon Stock | 757,432 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-017389 · doc1.xml · nonDerivative · entry 1 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · Director · Former 10% Owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · Former 10% Owner Cormorant Private Healthcare Fund III LP · CIK 0001817320 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 757,432 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of Series B Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund III, LP ("Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F3 · ownership.nature: Represents (i) 165,877 shares held by the Master Fund, (ii) 578,111 shares held by Fund III, and (iii) 13,444 shares held by the Account. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.